Tags

Type your tag names separated by a space and hit enter

Follow-up recommendations and risk-reduction initiatives for Lynch syndrome.

Abstract

Lynch syndrome is the most common inherited colon cancer susceptibility syndrome. Lynch syndrome is characterized by a significantly increased risk for colon cancer and endometrial cancer and a smaller risk for several other associated cancers. Some periodic screening strategies, such as colonoscopy, reduce the incidence and mortality of Lynch syndrome. The aim of this review is to discuss the risks, surveillance tests and guidelines for the management of colonic and extracolonic tumors associated with Lynch syndrome. For extracolonic cancer, a benefit of surveillance is evident only for endometrial cancer. No definitive data show efficacy of chemopreventive drugs, although aspirin is a promising drug. In this review, the available evidence on the different screening strategies in Lynch syndrome will be discussed. Furthermore, the clinical and biological characteristics of this disease and their potential impact on prevention in individuals at risk are analyzed.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain. carmenguillenponce@yahoo.es

    ,

    Source

    Expert review of anticancer therapy 12:10 2012 Oct pg 1359-67

    MeSH

    Colonic Neoplasms
    Colorectal Neoplasms, Hereditary Nonpolyposis
    Early Detection of Cancer
    Endometrial Neoplasms
    Female
    Humans
    Risk Factors

    Pub Type(s)

    Journal Article
    Review

    Language

    eng

    PubMed ID

    23176623

    Citation

    Guillén-Ponce, Carmen, et al. "Follow-up Recommendations and Risk-reduction Initiatives for Lynch Syndrome." Expert Review of Anticancer Therapy, vol. 12, no. 10, 2012, pp. 1359-67.
    Guillén-Ponce C, Molina-Garrido MJ, Carrato A. Follow-up recommendations and risk-reduction initiatives for Lynch syndrome. Expert Rev Anticancer Ther. 2012;12(10):1359-67.
    Guillén-Ponce, C., Molina-Garrido, M. J., & Carrato, A. (2012). Follow-up recommendations and risk-reduction initiatives for Lynch syndrome. Expert Review of Anticancer Therapy, 12(10), pp. 1359-67. doi:10.1586/era.12.114.
    Guillén-Ponce C, Molina-Garrido MJ, Carrato A. Follow-up Recommendations and Risk-reduction Initiatives for Lynch Syndrome. Expert Rev Anticancer Ther. 2012;12(10):1359-67. PubMed PMID: 23176623.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Follow-up recommendations and risk-reduction initiatives for Lynch syndrome. AU - Guillén-Ponce,Carmen, AU - Molina-Garrido,Maria-José, AU - Carrato,Alfredo, PY - 2012/11/27/entrez PY - 2012/11/28/pubmed PY - 2013/5/1/medline SP - 1359 EP - 67 JF - Expert review of anticancer therapy JO - Expert Rev Anticancer Ther VL - 12 IS - 10 N2 - Lynch syndrome is the most common inherited colon cancer susceptibility syndrome. Lynch syndrome is characterized by a significantly increased risk for colon cancer and endometrial cancer and a smaller risk for several other associated cancers. Some periodic screening strategies, such as colonoscopy, reduce the incidence and mortality of Lynch syndrome. The aim of this review is to discuss the risks, surveillance tests and guidelines for the management of colonic and extracolonic tumors associated with Lynch syndrome. For extracolonic cancer, a benefit of surveillance is evident only for endometrial cancer. No definitive data show efficacy of chemopreventive drugs, although aspirin is a promising drug. In this review, the available evidence on the different screening strategies in Lynch syndrome will be discussed. Furthermore, the clinical and biological characteristics of this disease and their potential impact on prevention in individuals at risk are analyzed. SN - 1744-8328 UR - https://www.unboundmedicine.com/medline/citation/23176623/Follow_up_recommendations_and_risk_reduction_initiatives_for_Lynch_syndrome_ L2 - http://www.tandfonline.com/doi/full/10.1586/era.12.114 DB - PRIME DP - Unbound Medicine ER -